Innovus Pharma (INNV) Reports Q1 Loss of $0.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 201
May 14, 2018 4:05 PM EDTQuarterly Net Revenue Increase of 109% When Compared to the First Quarter of 2017
SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc., (Innovus Pharma or the Company) (OTCQB: INNV), today announced first quarter 2018 net revenue of $4.5 million compared to $2.2 million in net revenue for the same period in 2017.
We are delighted with our first quarter net revenues of $4.5 million, which beat our previously announced first quarter expectations, stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. We are very confident in our business strategy and in our ability to grow our sales revenue... More
